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Background: Intestinal mucosal barrier dysfunction plays an important role in the
development of diabetes mellitus (DM). Berberine (BBR), a kind of isoquinoline alkaloid,
is widely known to be effective for both DM and diarrhea. Here, we explored whether
the anti-diabetic effect of BBR was related to the intestine mucosal barrier.
Methods and Results: The rat model of T2DM was established by high glucose
and fat diet feeding and intravenous injection of streptozocin. Then, those diabetic
rats were treated with BBR at different concentrations for 9 weeks. The results
showed, in addition to hyperglycemia and hyperlipidemia, diabetic rats were also
characterized by proinflammatory intestinal changes, altered gut-derived hormones,
and 2.77-fold increase in intestinal permeability. However, the treatment with BBR
significantly reversed the above changes in diabetic rats, presenting as the improvement
of the high glucose and triglyceride levels, the relief of the inflammatory changes of
intestinal immune system, and the attenuation of the intestinal barrier damage. BBR
treatment at a high concentration also decreased the intestinal permeability by 27.5%
in diabetic rats. Furthermore, BBR regulated the expressions of the molecules involved
in TLR4/MyD88/NF-κB signaling pathways in intestinal tissue of diabetic rats.
Conclusion: The hypoglycemic effects of BBR might be related to the improvement in
gut-derived hormones and the attenuation of intestinal mucosal mechanic and immune
barrier damages.
Keywords: berberine, diabetes, intestinal mucosal barrier, gut immune system, gut-derived hormones
INTRODUCTION
The number of diabetics underwent a four-fold change over the past 35 years, and worldwide
incidence of diabetes mellitus (DM) was about 9% in 2014 (Lancet, 2016a). In China, the incidence
was 11.6%, and the rate of prediabetes was 50.1% among adults. However, only 25.8% of diabetics
accepted hypoglycemic treatment, and only 39.7% population of the treated diabetic patients
Abbreviations: BBR, berberine; GIP, gastric inhibitory polypeptide; GLP-1, glucagon-like peptide-1; HGFD, high glucose
and fat diet; LP, lamina propria; LPS, lipopolysaccharide; MLN, mesenteric lymph nodes; OCLN, occludin-1; PPRs, pattern
recognition receptors; STZ, streptozotocin; T2DM, Type 2 diabetes.
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achieved eligible glucose control (Xu et al., 2013). In 2012, it was
reported that poor blood glucose control led to the deaths of 370
million diabetics (Lancet, 2016b). High mortality rate of diabetes
brings great health burden to the world populations, arousing
researchers to seek out new therapies of diabetes based on new
insight into the pathogenesis. Among these, the role of intestine
has attracted great concerns.
The intestinal immune system is the first defense line for
the contact with dietary antigens. Intestinal changes caused
by intestinal infection, oral milk or gluten protein antigens,
and varied intestinal flora has been confirmed involved in the
pathogenesis of DM (Luck et al., 2015). Prior to the occurrence
of diabetes, the intestinal morphology and gut immune system
have changed, and intestinal permeability increases (Graham
et al., 2004). On the other hand, mesenteric lymphocytes
transplantation of non-obese diabetic mice could transfer
diabetes to the recipient mice, which indicates DM-caused T
cells exist in the gut immune tissue (Antvorskov et al., 2014). As
is well known, T2DM is a chronic inflammatory disease; many
factors are associated with the onset of T2DM including intestinal
flora disturbance, immune tolerance deficiency, intestinal barrier
damage, pattern recognition receptor (PPRs) expressions changes
in intestinal epithelial and immune cells and gut hormone
change (Winer et al., 2016). With intestinal barrier defect,
LPS and other intestinal bacteria products filter into the
circulation and result in local and systemic chronic inflammation,
which makes islet beta cell dysfunction and insulin resistance
(Burcelin, 2012). However, the role of gut immune cells and
inflammation in the pathogenesis of DM are still not fully
explored.
Berberine (BBR, [C20H18NO4]+), a kind of isoquinoline
alkaloid, could play hypoglycemic and hypolipidemic roles in
clinical and experimental studies (Dong et al., 2012, 2013). Some
studies illuminated diversified action mechanisms of BBR for
treating diabetes. For example, BBR could increase the glucose
uptake and consumption in adipose and muscle cells, elevate
insulin receptor expressions of liver and muscle, and enhance
liver low density lipoprotein receptor expressions to decrease
serum cholesterol and glucose (Pirillo and Catapano, 2015).
Moreover, Th1 and Th17 cells differentiation and macrophage
trafficking could be blocked by BBR, thereby proinflammatory
cytokine secretions are reduced (Pirillo and Catapano, 2015).
However, BBR is extensively known as a medicine for the
treatment of diarrhea in China. In the gut, BBR could stimulate
the secretions of GLP-1, depress the activity of α-glucosidase and
reduce the intestinal absorption of glucose (Leng et al., 2004;
Turner et al., 2008; Zhao et al., 2012).
Taken the low oral bioavailability conundrum of BBR as well
as its effect on diarrhea into account (Pirillo and Catapano, 2015),
we hypothesized that BBR might prevent the development of
diabetes through its action on the intestines. Metformin have also
been shown to alter the intestinal flora, modulate gut hormones
and maintain the intestinal barrier integrity (Shin et al., 2014;
DeFronzo et al., 2016; Mardinoglu et al., 2016). Therefore, we
conducted a study to testify whether the hypoglycemic effects of
BBR as well as metformin were via preventing intestinal mucosal
barrier damage and stimulating gut hormones release.
MATERIALS AND METHODS
Animals, Grouping and Modeling
Male Wistar rats with weight between 160 and 180 g were
purchased from Hua Fukang Co., Ltd and bred in SPF
circumstances in the experimental animal center of Huazhong
University of Science and Technology. After acclimatization for
2 weeks, the rats were randomly divided into normal group
(NO group) and HGFD group (HGFD group). The rats in
NO group was fed with standard laboratory rat chow (the
formula contains 35% flour, 20% corn meal, 20% soy meal,
15.5% bran, 5% fish meal, 1% dusty yeast, 0.5% bean oil, 2.5%
bone meal, and 0.5% salt) while the diet in HGFD group
contained 67.5% standard laboratory rat chow, 12% lard, 2%
cholesterol, 0.5% bile salts and 20% sugar. The dietary regimens
of the rats in different groups were unchanged until the end
of the experiment. One month later, intravenous injection of
small dose streptozotocin (STZ, 24mg/kg) was conducted in the
rats of HGFD groups (Duca et al., 2015). Then the normal
95% confidence intervals at various time points in OGTT
were achieved according to the blood glucose of rats in NO
group. If the blood glucose was greater than 20% of the upper
limit of confidence interval at any time point, the rats were
chosen for further studies as successful models of diabetic
rats. Diabetic rats were further randomly divided into model
group (MO group) and treatment groups, with 12 rats in each
group. All experiments were approved by the animal ethics
committee of Huazhong University of Science and Technology
(NO.2015S508).
Preparation of BBR and Treatment
Methods
The treatment groups included BBR treatment groups with BBR
at high (BH group), middle (BM group), or low dose (BL group)
and metformin group (ME group). BBR was purchased from
Yabang Pharmaceutical Co. Ltd. in China (H20053180) and
dissolved with 0.5% carboxymethyl cellulose sodium glue. High,
medium and low dosages in BBR treatment groups were 375,
187.5 and 93.75 mg·kg−1·day−1 respectively (Leng et al., 2004).
Daily dose of metformin was 184 mg/kg for the rats in ME
treatment group. Daily lavage volume of each rat was 1 ml/100 g
weight, and the solution concentration was calculated according
to the lavage capacity. In addition, 0.5% sodium carboxymethyl
cellulose solution was intragastric administrated to the rats in NO
and MO groups. Gastric irrigation doses were adjusted weekly
based on rats’ weights for 9 weeks.
Sampling and Metabolic Studies
When the interventions were over, six rats in each group were
used for the detections of intestinal permeability and the other
six rats in each group were employed for metabolic studies and
sampling. When performing OGTT, rats were overnight fasting
for 12 h and 2 g/kg glucose was administrated. The blood from
tail veins of each rat were collected at 0, 30, 60, and 120 min after
the intragastric administration and the blood glucose levels were
detected using a glucose monitor (Roche, German).
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At the end of 9 weeks’ treatment, all experimental animals
were killed. Anesthesia was performed by intraperitoneal
injection with 50 mg/kg pentobarbital sodium. Abdominal aorta
blood sampling, intestines and MLN were collected under
sterile conditions. Samples were fixed with 4% formaldehyde or
preserved in−80◦C.
The concentration of serum insulin was detected by using
iodine radioimmunoassay kit (Jinding, China). For the detection
of triglyceride (TG) content, colorimetric assay (Mingdian,
China) was used.
Intestinal Histological Morphology
Studies
Intestine sections were stained using hematoxylin and eosin
(H&E) to assess the histological morphology. Transmission
electron microscope (Hitachi, Japan) was used to evaluate
the ultrastructural changes. Tissue blocks were fixed with
glutaraldehyde. After rinsing and dehydration in ethanol,
the tissues were embedded and sliced with ultramicrotome.
Following uranyl acetate and lead citrate double staining,
transmission electron microscope was used for the morphology
observation and taking pictures.
Intestinal Permeability Test
FITC-dextran (Sigma, FD-4, USA) perfusion assay was used
to detect intestinal epithelial permeability in the rats. After
anesthesia, abdominal middle incision and ileum incision 5 cm
distance from the appendix was performed and 10-cm-long ileal
segment was ligated with 2.0 silk thread. Subsequently, 1ml
FITC-dextran (10 mg/ml) was affused into the ligated intestinal
cavity. Intestines were returned back to the abdominal cavity
and kept wet by wrapping moist gauze and a plastic film.
Thirty minutes later, blood was collected from the abdominal
aorta. Serum was separated and fluorescence was detected with
a spectrophotometer (Synergy2, USA).
Flow Cytometry
Mesenteric lymph nodes was grinded with strainer mesh and
glass rods in the 1640 culture medium containing 2% FBS.
Erythrocyte was lysed and the supernatant was dismissed
after centrifugation. If the markers were expressed in the
cytoplasm and nucleus, FIX/PERM liquid was added to break
the cell membrane. Otherwise, the cells were incubated with
different antibodies for 30 min away from light and fixed with
1% paraformaldehyde. T cells were stained with CD3-FITC,
CD4-APC and CD8-PE (BD Bioscience, USA); Macrophages
were with CD11b-APC (BD Bioscience, USA) and CD68-FITC
(AbD Serotec, UK), Tregs were with CD4-APC and Foxp3-PE
(eBioscience, USA); dendritic cells (DC) were with OX62-FITC
(Abcam, UK). Flow cytometry (BD FACSCalibur, USA) was
applied for the detection of cells’ population.
Immunofluorescence Test
Intestinal tissues were separated, rinsed, fixed and cut following
paraffin embedding. After using the spontaneous fluorescence
quenching agent, the sections were immunostained overnight
with primary antibodies against NF-κB (CST, USA) with triton
damaging cell membranes. Then fluorescence second antibodies
were co-incubated at room temperature for 30 min. Following
the rinse, the sections were stained with DAPI (Sigma, USA) for
3 min and sealed. Finally, observation and taking photos were
performed under a Nikon fluorescence microscope.
Real-Time PCR Assay
After the extract of intestinal RNA with Trizol reagent (Takara,
China) and concentration determination of RNA, reverse
transcriptase kit (Takara, China) was used to synthetize the
cDNA. Then, amplification was conducted using SYBR premix
EX TaqTM kit (Takara, China) in StepOne PCR detetor (Stepone,
USA). Relative expressions of mRNA were calculated by 2−11CT.
The primer sequences are listed in Table 1.
Western Blot Assay
Proteins of intestines (different sampling volumes for various
antibodies) were separated through gel electrophoresis,
transferred onto NC membranes, and incubated with antibodies
against TLR4 (NOVUS, USA), Occludin-1 (OCLN, Gene Tex,
USA), ZO-1 (Invitrogen, USA), Claudin-1 ( Abcam, UK),
MyD88 (CST, USA), p-IKKβ (Gene Tex, USA),IKKβ (Gene Tex,
USA) and β-actin (Affinity, USA). The membranes were then co-
incubated with fluorescent second antibodies. Oddesy imaging
system was implemented to analyze the protein expressions.
ELISA
Amylin, GLP-1, GIP and Ghrelin (Ray Biotech, USA) levels in
serum were tested using ELISA Kit in line with the competitive
enzyme immunoassay principle. In brief, 100 µL serum was
added to each well and OD values were detected at 450 nm using
a spectrophotometer (Synergy2, USA).
Statistical Analysis
Data were analyzed by SPSS 20.0 software. Statistical significance
was assessed by ANOVA following K-S normality test. With
homogeneity of variance, significance between different groups
was evaluated by Bonferroni test; alternatively, Dunnett’s T3 test
was used. P-values < 0.05 suggested that significant differences
existed.
TABLE 1 | Primers for RT-PCR assay.
Gene Forward (5′→3′) Reverse (5′→3′)
LBP CCCAGACGCTGGATGTGATG TGATCTGAGATGGCAAAGTAGACC
CD14 CTTATGCTCGGCTTGTTGCTGT TAGCAGCGGACACTTTCCTCGT
IL-1β GTCGGGACATAGTTGACTTCAC GACTTGGCAGAGGACTTCAC
TNF-α CCAGGTTCTCTTCAAGGGACAA GGTATGAAATGGCAAATCGGCT
IL-10 GCTGGACAACATACTGCTGAC AATGCTCCTTGATTTCTGGG
IL-4 CTGTCACCCTGTTCTGCTTTCTC TTTCTGTGACCTGGTTCAAAGTGT
TGF-β AAGGACCTGGGTTGGAAGT CGGGTTGTGTTGGTTGTAGA
IL-6 AATCTGCTCTGGTCTTCTGGA CAGTATTGCTCTGAATGACTCTGG
MIF GACTTTTAGTGGCACGAGCG GCTTGCTGTAGTTGCGGTTCT
β-actin AGCCATGTACGTAGCCATCC CTCTCAGCTGTGGTGGTGAA
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FIGURE 1 | Berberine (BBR) is effective on maintaining glucose homeostasis. (A) Body weights of rats in each group. (B) OGTT of the rats after an oral
gavage of 2.0 g/kg glucose. Data presented as mean ± SE. P < 0.01 for NO vs. MO group at each time point; P < 0.05 for MO vs. BM group, MO vs. BH group
and MO vs. ME group at each time point; P < 0.05 for MO vs. BL group at 30 min after glucose administration. (C) AUC in OGTT. (D) IRI after the treatment.
(E) Serum insulin concentration of the rats. (F) Serum TG concentration. NO, normal control group; MO, diabetic model group; BL, BBR treatment group with a low
concentration; BM, BBR treatment group with a middle concentration; BH, BBR treatment group with a high concentration; ME, metformin treatment group; Data
presented as mean ± SD except OGTT. n = 6 rats in each group. ∗∗P < 0.01 vs. NO group, #P < 0.05 vs. MO group, ##P < 0.01 vs. MO group.
RESULTS
BBR Attenuates the Disturbance of
Glucose and Lipid Metabolism in
Diabetic Rats
Firstly, we detected the effects of BBR on glucose and
lipid metabolism in diabetic rats (Figure 1). Consistent with
previous study, diabetic rats underwent the weight loss after
modeling (Wang et al., 2016), and BBR interventions did
not significantly improve the decreased body weights. With
2 g/kg glucose lavage in OGTT, the blood glucose at each
time-point increased significantly in diabetic rats, whereas
BBR at middle (187.5 mg/kg) and high dosage (375 mg/kg)
reversed elevated fasting and postprandial blood glucose. The
area under the concentration-time curve (AUC) in OGTT and
serum TG levels also decreased in BBR-treated rats. Although
no significant difference was shown with regards to serum
insulin concentration in different groups, BBR decreased insulin
resistance index (IRI) as well as TG in diabetic rats of BM and
BH groups. These data indicated that BBR had specific beneficial
effects on metabolic parameters. Similar hypoglycemic and lipid-
lowering effects were observed in ME group that metformin was
administrated as a positive control.
BBR Changes the Proportion of Intestinal
Immune Cells in MLN of Diabetic Rats
Flow cytometry was used to detect the proportions of T cells,
macrophages and DC in MLN. As shown in Figure 2, the
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FIGURE 2 | Berberine increased Tregs and reduced macrophages percentages in MLN of diabetic rats. (A) Tregs populations in MLN (n = 4).
(B) Macrophage populations of different groups in MLN (n = 4 or 5). (C) Ratio of CD4+ and CD8+ cells on CD3+ gate (n = 5 or 6). (D) Dendritic cell populations in
MLN (n = 3). Data presented as mean ± SD. ∗∗P < 0.01 vs. NO group, #P < 0.05 vs. MO group, ##P < 0.01 vs. MO group.
percentage of Tregs in MLN of diabetic rats was decreased
while it was increased in BBR- and metformin-treated rats.
Because macrophages are the sources of many proinflammatory
factors, we studied the proportion differences of macrophages
with BBR administration. Significantly higher numbers of
CD11b + CD68+ MLN cells were observed in MO group while
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FIGURE 3 | Berberine affected mRNA expressions of intestinal cytokines and plasma gastrointestinal hormones. (A) IL-1β mRNA levels. (B) TNF-α
mRNA levels. (C) MIF mRNA levels. (D) IL-4 mRNA levels. (E) IL-10 mRNA levels. (F) Plasma GLP-1 concentrations. (G) Plasma GIP concentrations. (H) Plasma
Ghrelin concentrations. (I) Plasma Amylin concentrations. The levels of mRNA were expressed relative to the β-actin. Data presented as mean ± SD. n = 6 for each
group. *P < 0.05 vs. NO group, **P < 0.01 vs. NO group, #P < 0.05 vs. MO group, ##P < 0.01 vs. MO group.
less numbers were observed in BBR treatment and ME groups.
As far as CD4 + T cells, CD8+ T cells, the ratio of CD4+ to
CD8+ cells and DC were concerned, no significant changes were
found.
BBR Affects the Expressions of Intestinal
Immune Factors in Diabetic Rats
Intestinal immune factors involved in the maintenance of
intestinal immune tolerance and the intestinal barrier integrity.
Since BBR had the beneficial effect on immune cells of intestinal
immune system, it might also influence the expressions of
intestinal immune factors. The results showed that IL-1β, TNF-
α and MIF mRNA expressions were elevated in comparison with
NO group, while IL-4 and IL-10 mRNA levels were reduced in
intestinal tissue of diabetic rats (Figures 3A–E). However, BBR,
especially at high doses, showed significant inhibitory effects on
the expressions of IL-1β, MIF and TNF-αmRNA. Moreover, BBR
treatment also exhibited the increase in IL-4 and IL-10 mRNA
expressions in intestinal tissue of diabetic rats. Despite increased
tendency for IL-6 mRNA expression and decreased trend for
TGF-βmRNA expression in MO group, heterogeneity of variance
was large and no statistical difference was found in the treatment
groups (Data not shown).
BBR Regulates the Secretion of
Gastrointestinal Hormones in Diabetic
Rats
Since gastrointestinal hormones participate in glycemic
control, we next examined the effects of BBR on plasma
gastrointestinal hormones levels (Figures 3F–I). After HGFD
and the administration of STZ, GLP-1 and GIP secretion reduced
while pancreatic beta cells-derived Amylin increased in diabetic
rats (Figures 3F,I). The administration of BBR at different
concentrations increased the secretion of GLP-1, but only BBR at
a high dose influenced the production of GIP and Amylin. In the
analysis regarding Ghrelin, BBR at a high dose decreased Ghrelin
production compared with MO group, and no differences were
found between other different groups.
BBR Improves Intestinal Mucosal Barrier
Function in Diabetic Rats
High glucose and fat diet and intestinal inflammation could
disrupt the intestinal mucosal barriers, leading to endotoxemia
and the development of DM. Thus, we studied the effects
of BBR on intestinal tight junction proteins expressions and
mucosal barrier permeability. Tight junction protein OCLN,
ZO-1 and Claudin-1 expressions were detected using western
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FIGURE 4 | Berberine protects intestinal mucosal integrity. (A) OCLN expression in intestine. (B) ZO-1 expression in intestine. (C) Claudin-1 expression in
intestine. (D) Serum dextran concentration after the lumina infusion of FITC-dextran. The protein sampling mass was 150 or 200 µg. Data presented as mean ± SD.
n = 3 for the detections of OCLN, ZO-1 and Claudin-1 expressions; n = 6 for serum dextran concentration. ∗∗P < 0.01 vs. NO group, #P < 0.05 vs. MO group,
##P < 0.01 vs. MO group.
FIGURE 5 | Histology of small bowel with H&E staining after the
intestinal infusion of FITC-dextran. FITC-dextran was different under the
intestinal epithelium after intestinal perfusion. White arrowheads suggested
more fluorescent dextran underneath the intestinal epithelium was observed.
blot. Compared with the rats in NO group, these tight junction
proteins expressions were reduced in the intestine of untreated
diabetic rats. BBR treatment could partially increase OCLN
and ZO-1 expressions but it showed no effects on Claudin-1
levels (Figures 4A–C). After the intestinal perfusion of FITC-
dextran, BBR could reduce serum dextran concentration,
namely the intestinal barrier permeability (Figure 4D).
Although HE staining illustrated no significant change in
intestinal structure between these groups (Supplementary
Figure S1), the amount and distribution of filtered FITC-
dextran were different in intestinal mucosa and submucosa
tissues after intestinal dextran perfusion (Figure 5), which
also suggested differences of the intestinal permeability in the
rats of various groups. With regard to the ultrastructure of
intestinal epithelial cells, intercellular adhesions were damaged,
and the adherent junction in diabetic rats was sparse and
expanded. These changes were improved after BBR treatment
(Figure 6).
BBR Modulates the Expressions of the
Molecules Involved in
TLR4/MyD88/NF-κB Signaling Pathways
in Intestines of Diabetic Rats
Previous studies confirmed that BBR could protect islet beta cells
in DM, and also prevent intestinal inflammation in bowel disease
through depressing TLR4 signaling pathways (Zhang et al.,
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FIGURE 6 | Ultrastructure of intestinal intercellular junction in different groups. The figures revealed the disrupted and expanded adherens junctions of
intestinal epithelial cells in MO and BL groups, although the desmosome was visible in each group. Black arrowheads indicated damaged cell-cell adhesion and
wider gaps between adjacent intestinal epithelial cells. White arrowheads suggested the tight junctions.
2011). To ascertain whether the hypoglycemic and gut-protective
effects of BBR were mediated through anti-inflammatory signal
transduction pathways, we detected the expressions of TLR4 and
downstream MyD88 and p-IKKβ in the intestines, along with
p65 NF-κB distributions in epithelial cytoplasm and nucleus.
The results revealed BBR, especially at a high dose, reduced
intestinal TLR4 and MyD88 protein expressions as well as the
phosphorylation of IKKβ (Figures 7A–C). As a main ligand
for TLR4, LPS combined with LPS binding protein (LBP) and
CD14 to form the trimer; then the complex binds to the
TLR4 and activates inflammatory signal transduction pathways.
Data of RT-PCR illustrated intestinal LBP and CD14 mRNA
levels decreased in BBR-treated rats (Figures 7D,E). Accordingly,
Figure 8 showed p65 NF-κB distributions were different in
intestinal epithelial cells among different groups, and BBR
exerted a potential ability to blunt p65 NF-κB translocation to the
nuclei.
DISCUSSION
T2DM rat model was established by HGFD and intravenous
injection of 24 mg/kg STZ in this study (Duca et al., 2015).
Consistent with previous studies, decreased body weights were
observed after the STZ treatment (Wang et al., 2016). After BBR
delivery with the dose range between 93.75 and 375 mg/kg, the
hypoglycemic and hypolipidemic efficacies were shown in a dose-
dependent manner. Previous researches have shown that the
bioavailability of BBR was lower than 5% (Pirillo and Catapano,
2015), and it seems inexplicable for the valid hypoglycemic effects
with such low bioavailability. We then investigated whether
BBR exerted beneficial therapeutic impacts on DM through the
intestines.
Though human and rodent studies confirmed the proportion
changes of immune cells in gut LP of diabetic mice (Monteiro-
Sepulveda et al., 2015), the transplantation of MLN can transmit
diabetes to the recipient mice, which highlights the vital
pathogenic effects of MLN (Antvorskov et al., 2014; Winer
et al., 2016). Therefore we firstly focused on the immune
cells population alterations in the MLN of diabetic rats.
Consistent with the changes in intestinal LP, we observed
reduced Tregs and increased macrophages in diabetic rats, which
was inhibited by BBR treatment. Previous studies also found
CD4+, CD8+ and DC cells went through transformations
in LP (Monteiro-Sepulveda et al., 2015), but no significant
differences about aforementioned cells were discovered in the
present experiment. It might be explained by different high
fat diet or treatment duration, which led to the differentia in
intestinal bacteria spectrum and the variant activated immune
cells. Based on proinflammatory change of immune cells, we
observed that intestinal inflammatory cytokines IL-1β, TNF-
α and MIF-1 increased, and IL-10 and IL-4 which maintain
immune tolerance reduced in diabetic rats in the present
study. These intestinal cytokine changes in diabetic rats were
consistent with the data in clinical trials; namely, intestinal
cytokine’s milieu of healthy persons features high levels of
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FIGURE 7 | The gut-protective effects of BBR are related to TLR4/MyD88/NFκB signaling pathway. (A) TLR4 expressions in intestine (n = 4). (B) MyD88
expressions in intestine (n = 3). (C) Fold change of p-IKKβ/IKKβ ratios in intestine (n = 4). (D) The mRNA levels of CD14 (n = 6). (E) The mRNA levels of LBP (n = 6).
The levels of mRNA were expressed relative to the β-actin. The protein sampling mass was 200 µg for TLR4 and MyD88; while 100 µg for p-IKKβ and IKKβ. Data
presented as mean ± SD. ∗P < 0.05 vs. NO group, ∗∗P < 0.01 vs. NO group, #P < 0.05 vs. MO group, ##P < 0.01 vs. MO group.
sIgA and IL-10 (Fritz et al., 2012) while that of subjects
with metabolic disease features increased proinflammatory
cytokines in the intestinal LP and epithelium (Garidou et al.,
2015).
How did these pro-inflammatory changes occur in intestinal
immune system of diabetic rats? How did they affect the
development of DM? HGFD was found to induce decreased
expressions and abnormal distributions of intestinal tight
junction proteins, and then intestinal permeability was increased
(Everard et al., 2013; Wang et al., 2014). Once the mucosal
barrier was damaged, luminal LPS, DNA and other bacterial
products went through bowels, activated the immune cells
with the expressions of CD14 and TLR4 (Delzenne et al.,
2015; Plociennikowska et al., 2015; Winer et al., 2016), and
caused abnormal secretions of immune cytokine (He et al.,
2016). With proinflammatory cytokines binding to responding
receptors, insulin signaling pathways were interfered, and
abnormal insulin secretion and insulin resistance emerged
(Caricilli et al., 2011). Besides, in chronic inflammatory state
of DM, proinflammatory cytokines such as IL-1β, IL-6 and
TNF-α aggravated the impairment in intestinal mucosal barrier
(Winer et al., 2016). In the present study, tight junction
proteins OCLN, ZO-1 and Claudin-1 expressions were decreased,
and serum FITC-dextran was increased after the luminal
dextran perfusion in diabetic rats. BBR seemed to protect
the intestinal barrier integrity through modulating ZO-1 and
OCLN expressions; however, BBR did not influence the Claudin-
1 level in our study. Claudin-1 is a member of claudin
family and an essential component in intestinal mucosal barrier
forming. The intestinal proinflammatory immune factor and
NF-κB could induce the decrease in claudin-1 expression
inflammatory bowel disease (Zhou et al., 2009), and BBR might
regulate claudin-4 and claudin-2 expressions other than claudin-
1 in claudin family (Amasheh et al., 2010; Li et al., 2014).
In the present study, we also found that BBR could blunt
TLR4 expression and attenuate local metabolic inflammation
possibly through suppressing TLR4/MyD88/IKKβ signaling
pathways in intestinal tissue. It might be one of the molecular
mechanisms for BBR to protect the intestinal mucosal barrier
and inhibit the proinflammatory changes in the treatment
of DM.
Additionally, we observed the secretion of GLP-1 and
GIP was reduced in diabetic rats, and the concentration of
Amylin was increased despite of no significant change of
Ghrelin. BBR, especially at a high concentration, prevented the
aberrant changes of the hormones, which might be related to
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FIGURE 8 | Representative immunofluorescence staining images of
p65 NF-κB in small bowels. Transcription factor NF-κB is widely expressed
in the intestines, and the distribution in nucleus and cytoplasm is different
under various conditions. The results suggested the distributions of p65
NF-κB (red) were different in the cytoplasm and nuclei of intestinal epithelium
among different groups. Nuclei were stained blue with DAPI. BBR might
reduce the translocation of p65 NF-κB into the nuclei (pink). White
arrowheads indicated the distributions of p65 NF-κB in the nuclei of intestinal
epithelial cells.
its inhibitory effects on intestinal proinflammatory cells and
cytokines. These gastrointestinal hormones GLP-1, GIP and
Ghrelin, and pancreatic beta cells-derived Amylin, can modulate
glucose metabolism (Westwell-Roper et al., 2014). Intestinal
immune molecules could also affect GLP-1 secretion from ileal
L cells, and anti-TNF-α therapy could reverse high fat diet
induced reduction of GLP-1 in diabetic mice (Everard et al.,
2013; Anhe et al., 2015; Luck et al., 2015; Yusta et al., 2015).
Doubtfully, Ghrelin concentrations in the rats of NO group
appeared to be higher than those of BH group despite of
no statistically significance. Ghrelin was secreted from gastric
P/D1 cells and pancreatic ε cells, which was influenced by
many factors such as STZ, HGFD, gut microbiota, bitter taste
receptors, and so on (Janssen et al., 2011); STZ could increase
its secretion (Muller et al., 2015) while high-fat diet could
reduce its secretion (Little and Feinle-Bisset, 2011). Previous
study had proved that BBR might regulate the secretion of
GLP-1 via intestinal bitter taste receptor in enteric L cells (Yu
et al., 2015). Further studies are required to confirm whether
BBR could influence bitter taste receptors in ghrelin-secreting
cells.
The intestinal improvements in the diabetic rats receiving BBR
administration gave rise to question whether intestines were the
exclusive hypoglycemic action sites of BBR. When the absorption
rate of BBR was enhanced, the hypoglycemic effect was better
(Zhaojie et al., 2014; Pirillo and Catapano, 2015). Therefore, BBR
may exert its anti-diabetic effect through multiple ways, and the
target in the intestine is probably just one of them. Consistent
with preceding studies, the positive control metformin could
promote the secretion of GLP-1 (McCreight et al., 2016).
Although metformin had obvious gastrointestinal side-effect in
patients, it exhibited a protective effect on the expression of
OCLN. In addition, metformin could reduce TLR4 expressions,
increase Tregs and decrease the proportion of macrophages.
Such effects might be related to the increased expression of
intestinal probiotics as previously reported (Forslund et al.,
2015).
Intestinal immune system, endocrine system, mucosal barrier
and gut microbiota interact with each other and have cross-
talks, but the initial lesion and subsequent reaction are not
fully clear. Further elaborate in vivo and ex vivo experiments
need to be performed to confirm BBR preliminary acts on one
or some of the sites. Taken together, these findings suggested
the abnormities of intestinal mucosal barrier, immune system,
endocrine and PPRs in diabetic rats. However, BBR could
improve the barrier function defect, depress the proinflammatory
changes of intestinal immune cells and cytokines, and change
aberrant gut-derived hormones which might be pharmacological
mechanisms for treating diabetes. However, the interaction
among them and the exact anti-diabetic mechanism of BBR need
to be further studied.
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